Tyrosine kinase inhibitors in acute and chronic leukemias

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 7, 2012, Pages 927-938

  Ohanian, Maro ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myelogenous leukemia; Chronic myelogenous leukemia; Philadelphia chromosome positive acute lymphoblastic leukemia; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; BILIRUBIN; BOSUTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FLT3 LIGAND; GLYCOPROTEIN P; IDARUBICIN; IMATINIB; LESTAURTINIB; METHOTREXATE; MIDOSTAURIN; NILOTINIB; PANCREAS ENZYME; PHOSPHATE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PONATINIB; PREDNISONE; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; SORAFENIB; TRIACYLGLYCEROL LIPASE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOTRANSPLANTATION; ANEMIA; ARTHRALGIA; BINDING AFFINITY; BONE MARROW SUPPRESSION; BONE MINERALIZATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLITIS; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG BINDING; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GENE AMPLIFICATION; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; MUSCLE CRAMP; MUSCLE SPASM; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ONCOGENE C KIT; OVERALL SURVIVAL; PANCREATITIS; PERICARDITIS; PERIPHERAL EDEMA; PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84860174035     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.672974     Document Type: Review

References (74)

1. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42 (Pubitemid 32267973)
2. European Medicines Agency, Committee for Orphan Medicinal Products. Public summary of positive opinion for orphan designation of imatinib mesilate for treatment of chronic myeloid leukaemia. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/Orphan-designation/2009/10/WC500006437. pdf [Last accessed 27 March 2012]
3. Highlights of prescribing. Gleevec prescribing information. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/gleevec-tabs.pdf [Last accessed 27 March 2012]
4. Johnson JR, Bross JR, Cohen M, et al. Report from the FDA: approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 2003;9:1972-9 (Pubitemid 36687615)
5. Palandri F, Iacobucci I, Castagnetti F, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 2008;93:770-4 (Pubitemid 351669320)
6. Druker B, Guilhot F, O'Brien S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17 (Pubitemid 44903745)
7. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63 (Pubitemid 350248462)
8. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
9. O'Brien S, Berman E, Moore J, et al. NCCN Task Force Report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011;9(Suppl 2):S1-25
10. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004 (Pubitemid 36302244)
11. Deininger M, O'Brien S, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract 1126]. Blood 2009;114:462
12. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
13. Lucas C, Wang L, Austin G, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008 Oct;22(10):1963-6
14. Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003;98:1105-13 (Pubitemid 37099894)
15. Jabbour E, Cortes J, Kantarjian H. Chronic myeloid leukemia. Emerging Cancer Therapies (ECAT). Leukemia 2011;2:239-58
16. Mathisen M, Kantarjian H, Cortes J, Jabbour E. Mutant BCR-ABL clones in chronic myeloid leukemia. Haematologica 2011;96:347-9
17. Chu E, DeVita E. Cancer Chemotherapy Drug Manual. Jones & Bartlett; 2010
18. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25 (Pubitemid 41039112)
19. Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology 2009;4:61-76
20. Ravandi F. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 2011;11:198-203
21. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80 (Pubitemid 32743979)
22. White D, Saunders V, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704 (Pubitemid 44061372)
23. Thomas J, Wang L, Clark R, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45 (Pubitemid 39564452)
24. Cortes J, Moshe T, Bixby D, et al. A phase I trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings [abstract]. Presented at the American Society of Hematology Annual Meeting and Exposition; 4-7 December 2010; Orlando, Florida, USA. Available from: http://ashconfexcom/ash/2010/webprogram/Paper31434html 2010 [Last accessed 27 March 2012]
25. Jabbour E, Branford S, Saglio G, et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011;117:1800-11
26. Nilotinib FDA information. http://www. accessdata.fda.gov/drugsatfda- docs/label/2011/022068s006lbl.pdf, [Last accessed 27 March 2012]
27. Dasatinib, Sprycel. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/021986s7s8lbl.pdf Bristol-Myers Squibb Company [Last accessed 27 March 2012]
28. Novartis Pharmaceuticals Corporation Available from: http://www.us. tasigna. com/patient/full-prescribing-information
29. Sprycel package insert. Available from: http://packageinserts.bms.com/pi/ pi-sprycel.pdf Bristol-Myers Squibb [Last accessed 27 March 2012]
30. Kantarjian H, Gatterman N, Hochhaus A, et al. A Phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) [abstract #2169]. Blood 2006;108:2169
31. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-6 (Pubitemid 351833788)
32. Cortes J, Kantarjian H, Brummendorf T, Kim D. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood 2011;118:4567-76
33. Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 2007;110(6):1178-86 (Pubitemid 47435586)
34. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112(4):1005-12
35. Dasatinib gets new EU indication for chronic myelogenous leukemia. Available from: http://www.medconnect.com.sg/tabid/92/s3/Oncology/ct1/c39473/ Dasatinib-Gets-New-EU-Indication-for-Chronic-Myelogenous-Leukemia/Default.aspx
36. Mauro MJ, Baccarani F, Cervantes JH, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract 7009] (ASCO Annual Meeting Abstracts). J Clin Oncol 2009;26
37. Apperley J, Cortes J, Kim D, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial. J Clin Oncol 2009;27:3472-9
38. Kantarjian H, Cortes J, Kim DW, et al. Phase III study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-9
39. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352-9 (Pubitemid 351226100)
40. Cortes J, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia [abstract 7009] (ASCO Annual Meeting Abstracts). J Clin Oncol 2010;28:(3)398-404
41. Carpiuc K, Stephens J, Liou S, Botteman M. Incidence of grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CP-CML): a comparison of nilotinib and dasatinib [abstract 7009] (ASCO Annual Meeting Abstracts). J Clin Oncol 2007;26:Abstract 17501
42. Radich J, Kopecky K, Kamel-Reid S, et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup Trial. ASH Annual Meeting Abstracts 2010;116:LBA-6
43. Wang S, Lange T, Niederwieser D, et al. Nilotinib induced remission of central nervous system relapse of imatinib-resistant PH+ CML after allogeneic haematopoietic cell transplantation. Presented at the 36th Annual Meeting of the European Group for Blood and Marrow Transplantation Vienna, Austria; 22 March 2010
44. EPAR summary for the public (Nilotinib). Available from: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/ 000798/WC500034396.pdf
45. Kantarjian H, Giles F, Bhalla K, Pinilla-Ibarz J. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141-5
46. Hochhaus A, Giles F, Apperley J, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase II study [abstract 0631]. Haematologica 2009;94(Suppl 2):256
47. Tasigna package insert. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2007/022068lbl. pdf
48. Cortes J, Jones D, O'Brien S, et al. Nilotonib as front-line therapy for patients with chronic myeloid leukemia in early chronic phase [abstract 7009] (ASCO Annual Meeting Abstracts). J Clin Oncol 2010;28:(3)392-7
49. Rosti G, Castagnetti F, Gugliotta G, et al. Excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph(+) chronic myeloid leukemia (CML): results of a phase II GIMEMA CML WP clinical trial [abstract 359] (ASH Annual Meeting Abstracts). Blood 2010;116:36
50. O'Brien S. Abstracts and notes on CML presentations ASH 2010 Orlando. ASH 2010 CML report 2010, 8 December 2010:1-36. Available from: http://www. spirit-cml.org/media/80068/ash 2010 cml report.pdf [Last accessed March 27 2012]
51. Gillis B. ASH 2010: bosutinib shows promise as first-line treatment of chronic myelogenous leukemia. Available from: http://www.onclive.com/ publications/obtn/2010/December-2010/ash-2010-bosutinib-shows-promise-as-first- linetreatment-of-chronic-myelogenous-leukemia 2010 [Last accessed March 27 2012]
52. Gambacorti-Passerini C, Kim D, Kantarjian M, et al. An ongoing phase III study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. ASH Annual Meeting Abstracts 2010;116:208
53. Cortes J, Kim D-W, Pinilla-Ibarz J, et al. Initial findings from the PACE trial: a pivotal phase II study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation [abstract 109]. Presented at American Society of Hematology (ASH) 2011, meeting update. Blood 2011;118:52. Available from: http://ash.confex.com/ash/2011/ webprogram/Paper41105.htm [Last accessed 27 March 2012]
54. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407 (Pubitemid 38745962)
55. Thomas, Deborah A, Faderl, et al. Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract 2738] (ASH Annual Meeting Abstracts). Blood 2004;104:Abstract 2738
56. Ravandi F, O'Brien S, Thomas D, et al. First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116:2070-7
57. Topaly W, Zeller J, Fruehauf S, et al. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Nature 2001;15:342-7 (Pubitemid 32243766)
58. Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005;19:1509-16
59. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009;27:5175-81
60. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108:1469-77 (Pubitemid 44316110)
61. Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program Book 2011;231-7
62. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-8 (Pubitemid 36077594)
63. Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011;118:6521-8
64. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109:3676-8 (Pubitemid 46641715)
65. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35 (Pubitemid 34627197)
66. Gilliland D, Griffin J. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42 (Pubitemid 34925124)
67. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233-9 (Pubitemid 32946520)
68. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-62
69. Fullmer A, Kantarjian H, Jabbour E, et al. Novel and targeted therapies in leukemia. Emerg Cancer Ther 2011;2:389-409
70. Serve H, Wagner R, Sauerland C, et al. Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled phase II trial [abstract 333]. Blood 2010;116:333
71. Cortes J, Foran J, Ghirdaladze D, et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase I AML study [abstract 636]. Blood 2009;114:636
72. Stone R, Fischer T, Paquette R, et al. A phase Ib study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3 [abstract 634] (ASH Annual Meeting Abstracts). Blood 2009;114:634
73. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011;117:3294-301
74. Pellicano F, Sinclair A, Holyoake TL. In search of CML stem cells' deadly weakness. Curr Hematol Malig Rep 2011;6:82-7